19 terminated. 19 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Terminated 19 |
| Phase 2 | 1 | Terminated 1 |
Follow Refractory Chronic Lymphocytic Leukemia: new trials by email Literature Review of Refractory Chronic Lymphocytic Leukemia trials Research Report on Refractory Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies BGB-21447 - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | BeOne Medicines | 51 | 2023-06-20 | 2026-07-14 |
| A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome VIP152, BTKi - Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Vincerx Pharma, Inc. | 6 | 2021-12-16 | 2023-11-18 |
| CD19-Specific T Cells Post AlloSCT Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine - B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-06-26 | 2021-06-02 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Laboratory Biomarker Analysis, ROR1 CAR-specific Autologous T-Lymphocytes - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 21 | 2016-03-16 | 2022-08-31 |
| Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Buparlisib, Ibrutinib, Ofatumumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 1 | Terminated | Emory University | 1 | 2016-01-01 | 2019-09-03 |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 72 | 2014-09-01 | 2015-08-20 |
| Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia alvespimycin hydrochloride, diagnostic laboratory biomarker analysis, pharmacogenomic studies - B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 30 | 2010-05-01 | 2015-11-04 |
| Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 9 | 2010-04-01 | 2015-11-11 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) Bendamustine Hydrochloride, Alemtuzumab - Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Case Comprehensive Cancer Center | 9 | 2008-11-01 | 2013-08-22 |
| Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia obatoclax mesylate, fludarabine phosphate, rituximab - B-cell Chronic Lymphocytic Leukemia, Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 28 | 2008-01-01 | 2013-09-30 |
| SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia SJG-136 - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Terminated | National Cancer Institute (NCI) | 25 | 2005-12-01 | 2013-09-30 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
| 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia tanespimycin, rituximab - B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 30 | 2005-04-01 | 2013-06-04 |
| 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer tanespimycin, bortezomib - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 74 | 2005-04-01 | 2013-06-04 |
| Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma oxaliplatin, etoposide - Angioimmunoblastic T-cell Lymphoma, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 40 | 2004-11-01 | 2014-02-24 |
Leukemia, Lymphocytic, Chronic, B-Cell (19) · Lymphoma, Large B-Cell, Diffuse (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Lymphoma, Mantle-Cell (7) · Burkitt Lymphoma (6) · Lymphoma, Follicular (6) · Lymphoma, Non-Hodgkin (6) · Lymphoma, B-Cell, Marginal Zone (5) · Intraocular Lymphoma (4) · Leukemia, Hairy Cell (4) · Leukemia, Prolymphocytic (4) · Mycosis Fungoides (4) · Sezary Syndrome (4) · Waldenstrom Macroglobulinemia (4) · Blast Crisis (3)
Chronic Disease (19) · Disease Attributes (19) · Hematologic Diseases (19) · Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Leukemia, B-Cell (19) · Leukemia, Lymphoid (19) · Lymphatic Diseases (19) · Lymphoproliferative Disorders (19) · Neoplasms (19) · Neoplasms by Histologic Type (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Leukemia (17)
Rituximab (5) · Cyclophosphamide (3) · Bendamustine Hydrochloride (2) · Bortezomib (2) · Doxorubicin (2) · Oxaliplatin (2) · Specimen Handling (2) · fludarabine phosphate (2) · ibrutinib (2) · obatoclax (2) · tanespimycin (2) · 1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione) (1) · 130-nm albumin-bound paclitaxel (1) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · 2C4 antibody (1)
National Cancer Institute (NCI) (10) · BeOne Medicines (1) · Case Comprehensive Cancer Center (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · Vincerx Pharma, Inc. (1) · Wake Forest University Health Sciences (1)
United States (19) · Australia (1) · Canada (1) · China (1) · New Zealand (1) · Poland (1)
Ajay Gopal (1) · David Maloney (1) · Farhad Ravandi-Kashani (1) · Francisco J Hernandez-ILizaliturri (1) · Jeffrey Jones (1) · Jennifer Brown (1) · Jonathon Cohen, MD, MS (1) · Joseph Flynn (1) · Kristie Blum (1) · Lara Davis, MD (1) · Lisa McGregor (1) · Matt Kalaycio, MD (1) · Paolo Caimi, MD (1) · Partow Kebriaei (1) · Richard Aplenc (1)
PMID 23256542, PMID 23393050, PMID 33357452, PMID 34515338, PMID 36873868, PMID 37882668, PMID 39863139
U01CA076576 (3), P30CA016058 (2), 2025 (1), P30CA012197 (1), P30CA021765 (1), R01CA114536 (1), R21CA115048 (1), R21CA119519 (1), U01CA062461 (1), U01CA062490 (1), U01CA097452 (1), U01CA121947 (1)